Previous 10 | Next 10 |
Cerus Corporation (Nasdaq: CERS) today announced that the Company will participate in two upcoming investor conferences. William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present at the Baird 2019 Global Healthcare Conference on W...
VistaGen Therapeutics ( OTC:VTGN ) initiated with Outperform rating and $7 (+999% upside) price target at William Blair. Shares up 8% premarket. More news on: VistaGen Therapeutics, Inc., Catalent, Inc., Cerus Corporation, Healthcare stocks news, Stocks on the move, , Read ...
Repligen (NASDAQ: RGEN ) resumed with Overweight rating and $110 (19% upside) price target at Stephens. More news on: Repligen Corporation, ZIOPHARM Oncology, Inc., Cerus Corporation, Healthcare stocks news, , Read more ...
Cerus Corporation ( CERS ) recently publicized their Q2 earnings results with a slight miss on EPS and a slight beat on revenue. The company continues to record steady revenue growth, while still making progress in their promising pipeline. Unfortunately, the stock remains stagnant and is ...
Cerus Corporation (CERS) Q2 2019 Earnings Conference Call August 01, 2019, 04:30 PM ET Company Participants Lainie Corten - VP of IR Obi Greenman - President and CEO Vivek Jayaraman - Chief Commercial Officer Kevin Green - CFO Carol Moore - SVP, Regulatory Affairs & Quali...
Cerus (NASDAQ: CERS ): Q2 GAAP EPS of -$0.13 misses by $0.02 . More news on: Cerus Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2019. Recent developments and highlights include: Total second quarter revenue of $22.5 million Record quarterly product revenue of $18.2 million, an 18% increase compared to...
Cerus Corporation (Nasdaq:CERS) announced today that its second quarter 2019 results will be released on Thursday, August 1, 2019, after the close of the stock market. The company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the ...
Cerus Corporation (Nasdaq:CERS) announced today that multiple abstracts featuring the INTERCEPT Blood System pathogen reduction technology, including four oral presentations, will be included in the scientific program at the 29 th regional congress of International Society of Blood Transfusi...
Cerus Corporation (Nasdaq:CERS) announced today a new corporate branding campaign building upon the Company’s leadership position in helping to safeguard the world’s blood supply and the planned relocation of its corporate offices to a new facility in Concord California. The ne...
News, Short Squeeze, Breakout and More Instantly...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discu...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain an...
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th...